Effects of BCG, Corynebacterium Parvum, and Methanol-extration Residue in the Reduction of Mortality from Staphylococcus Aureus and Candida Albicans Infections in Immunosuppressed Mice

Overview

Journal Infect Immun

Publisher American Society for Microbiology

Specialty Allergy & Immunology

Date 1975 Dec 1

PMID 1107224

Citations 21

Authors

N A Sher

S D Chaparas

L E Greenberg

S Bernard

Affiliations

Soon will be listed here.

Abstract

An immunosuppressed mouse model was devised to test the effects of immunopotentiators on the prevention of bacterial and fungal infections. The effects of BCG and Corynebacterium were tested against Staphylococcus aureus and Candida albicans infection. The effect of methanol-extraction residue (MER-BCG) was tested against S. aureus septicemia. CDF mice were given various doses of BCG, 1.0 mg of C. parvum, or 0.5 mg of MER intraperitoneally at varying intervals before injection of an intravenous bacterial challenge. Four days before challenge, 300 mg of cyclophosphamide per ml was given intraperitoneally. BCG (106 colony-forming units) reduced mortality due to S.aureus at pretreatment intervals of 3, 7, 14, and 28 days. Isonicotinic acid hydrazide treatment elimated the protective effect of the live BCG. C. parvum was as effective as BCG against S. aureus septicemia when given 3 days before infection, but lost most of its protective effect after that time. MER protected at doses as small as 0.25 mg when given 25 days prior to challenge. Both BCG and C. parvum exerted a protective effect against Candida albicans infection.

Citing Articles

Evidence for Anti-Viral Effects of Complete Freund's Adjuvant in the Mouse Model of Enterovirus Infection.

Gangaplara A, Massilamany C, Lasrado N, Steffen D, Reddy J Vaccines (Basel). 2020; 8(3).

PMID: 32645845 PMC: 7563290. DOI: 10.3390/vaccines8030364.

ERS International Congress, Madrid, 2019: highlights from the Basic and Translational Science Assembly.

Ubags N, Baker J, Boots A, Costa R, El-Merhie N, Fabre A ERJ Open Res. 2020; 6(1).

PMID: 32154289 PMC: 7049707. DOI: 10.1183/23120541.00350-2019.

The Unspecific Side of Acquired Immunity Against Infectious Disease: Causes and Consequences.

Muraille E Front Microbiol. 2016; 6:1525.

PMID: 26793171 PMC: 4707229. DOI: 10.3389/fmicb.2015.01525.

Innate immune memory: implications for development of pediatric immunomodulatory agents and adjuvanted vaccines.

Levy O, Netea M Pediatr Res. 2013; 75(1-2):184-8.

PMID: 24352476 PMC: 3973534. DOI: 10.1038/pr.2013.214.

Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity.

Ami Y, Izumi Y, Matsuo K, Someya K, Kanekiyo M, Horibata S J Virol. 2005; 79(20):12871-9.

PMID: 16188989 PMC: 1235843. DOI: 10.1128/JVI.79.20.12871-12879.2005.

References

Powles R . Immunotherapy for acute myelogenous leukaemia. Br J Cancer Suppl. 1973; 1:262-5. PMC: 2149078. View

Stockman G, Heim L, South M, TRENTIN J . Differential effects of cyclophosphamide on the B and T cell compartments of adult mice. J Immunol. 1973; 110(1):277-82. View

Hughes W . Fatal infections in childhood leukemia. Am J Dis Child. 1971; 122(4):283-7. DOI: 10.1001/archpedi.1971.02110040067003. View

Blanden R, LEFFORD M, Mackaness G . The host response to Calmette-Guérin bacillus infection in mice. J Exp Med. 1969; 129(5):1079-107. PMC: 2138639. DOI: 10.1084/jem.129.5.1079. View

Dannenberg Jr A . Cellular hypersensitivity and cellular immunity in the pathogensis of tuberculosis: specificity, systemic and local nature, and associated macrophage enzymes. Bacteriol Rev. 1968; 32(2):85-102. PMC: 378299. DOI: 10.1128/br.32.2.85-102.1968. View

Pollard M, Sharon N . Chemotherapy of spontaneous leukemia in germfree AKR mice. J Natl Cancer Inst. 1970; 45(4):677-80. View

STIFFEL C, Mouton D, BOUTHILLIER Y, DECREUSEFOND C, BIOZZI G . [Response of the RES to Mycobacterium tuberculosis (BCG) and Corynebacterium parvum in mice of different strains]. J Reticuloendothel Soc. 1970; 7(2):280-93. View

Smith L, Woodruff M . Comparative effect of two strains of C. parvum on phagocytic activity and tumour growth. Nature. 1968; 219(5150):197-8. DOI: 10.1038/219197a0. View

HALPERN B, PREVOT A, BIOZZI G, STIFFEL C, Mouton D, MORARD J . [STIMULATION OF THE PHAGOCYTIC ACTIVITY OF THE RETICULOENDOTHELIAL SYSTEM BY CORYNEBACTERIUM PARVUM]. J Reticuloendothel Soc. 1964; 1:77-96. View

10.

Senterfitt V, Shands J . Salmonellosis in Mice Infected with Mycobacterium bovis BCG II. Resistance to Infection. Infect Immun. 1970; 1(6):583-6. PMC: 415945. DOI: 10.1128/iai.1.6.583-586.1970. View

11.

Weiss D . Enhanced resistance of mice to infection with Pasteurella pestis following vaccination with fractions of phenol-killed tubercle bacilli. Nature. 1960; 186:1060-1. DOI: 10.1038/1861060a0. View

12.

Weiss D, BONHAG R, Parks J . STUDIES ON THE HETEROLOGOUS IMMUNOGENICITY OF A MENTHANOL-INSOLUBLE FRACTION OF ATTENUATED TUBERCLE BACILLI (BCG). I. ANTIMICROBIAL PROTECTION. J Exp Med. 1964; 119:53-70. PMC: 2137800. DOI: 10.1084/jem.119.1.53. View

13.

Rosenthal S, KENNIEBREW A, RAISYS N . A modified semi-solid medium and technique for determining viability of BCG. Acta Tuberc Pneumol Scand. 1962; 42:167-72. View

14.

DUBOS R, Schaedler R . Effects of cellular constituents of mycobacteria on the resistance of mice to heterologous infections I. Protective effects. J Exp Med. 1957; 106(5):703-17. PMC: 2136819. DOI: 10.1084/jem.106.5.703. View

15.

Weiss D . Nonspecific stimulation and modulation of the immune response and of states of resistance by the methanol-extraction residue fraction of tubercle bacilli. Natl Cancer Inst Monogr. 1972; 35:157-71. View

16.

Adlam C, Broughton E, Scott M . Enhanced resistance of mice to infection with bacteria following pre-treatment with Corynebacterium parvum. Nat New Biol. 1972; 235(59):219-20. DOI: 10.1038/newbio235219a0. View

17.

VOGLER W, Chan Y . Prolonging remission in myeloblastic leukemia by tice-strain bacillus Calmette-Guérin. Lancet. 1974; 2(7873):128-31. DOI: 10.1016/s0140-6736(74)91556-6. View

18.

Levine A, Graw Jr R, Young R . Management of infections in patients with leukemia and lymphoma: current concepts and experimental approaches. Semin Hematol. 1972; 9(2):141-79. View

19.

Larson C, USHIJIMA R, Karim R, Baker M, Baker R . Herpesvirus hominis type 2 infections in rabbits: effect of prior immunization with attenuated Mycobacterium bovis (BCG) cells. Infect Immun. 1972; 6(4):465-8. PMC: 422560. DOI: 10.1128/iai.6.4.465-468.1972. View

20.

Levine A, Siegel S, Schreiber A, Hauser J, Preisler H, Goldstein I . Protected environments and prophylactic antibiotics. A prospective controlled study of their utility in the therapy of acute leukemia. N Engl J Med. 1973; 288(10):477-83. DOI: 10.1056/NEJM197303082881001. View